1-Methoxy-3-methyl-2-butanamine hydrochloride | 1185294-54-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Methoxy-3-methyl-2-butanamine hydrochloride
• 英文别名: 1-methoxy-3-methylbutan-2-amine;hydrochloride
• CAS: 1185294-54-5
• 化学式: C6H16ClNO
• 分子量: 153.65
• InChiKey: MELMFNVCMMMNKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (Z)-ethyl 3-(dimethylamino)-2-(2-fluoro-5-iodobenzoyl)acrylate 、 1-Methoxy-3-methyl-2-butanamine hydrochloride 、 potassium carbonate 在 potassium carbonate 、 盐酸 、 水 、 乙酸乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 50.0h， 以to provide ethyl 6-iodo-1-(1-methoxy-3-methylbutan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (623 mg, 60%)的产率得到Ethyl 6-iodo-1-(1-methoxy-3-methylbutan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF

  摘要：

  描述了式(I)的化合物及其药学上可接受的盐。还描述了它们的制备过程、含有它们的制药组合物、它们作为药物的使用以及它们在治疗细菌感染方面的使用。

  公开号：

  US20100190745A1

文献信息

• [EN] HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES D'URÉE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2009147433A1

  公开（公告）日：2009-12-10

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药用盐。还描述了它们的制备过程、含有它们的药物组成、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20190263805A1

  公开（公告）日：2019-08-29

  The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及新颖的7-取代的1-芳基喹啉并吡啶-3-羧酰胺，其制备方法，其单独或组合使用，用于治疗和/或预防疾病，以及用于生产药物以治疗和/或预防疾病，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists
  申请人：Alcaraz Lilian

  公开号：US20090062259A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta adrenoreceptor agonists.

  本发明涉及式(I)的化合物，其制备方法，该方法的中间体化合物以及化合物在制造治疗ARDS、肺气肿、支气管炎、支气管扩张、COPD、哮喘和鼻炎等疾病的药物中的应用。这些化合物是β-肾上腺素受体激动剂。
• Heterocyclic urea derivatives and methods of use thereof
  申请人：AstraZeneca AB

  公开号：US08283361B2

  公开（公告）日：2012-10-09

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐。还描述了制备它们的过程，含有它们的制药组合物，它们作为药物的用途以及它们在治疗细菌感染方面的用途。
• 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
  申请人：Bayer Aktiengesellschaft

  公开号：US10927109B2

  公开（公告）日：2021-02-23

  The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及新型 7-取代 1-芳基萘啶-3-羧酰胺、其制备工艺、其单独或组合用于治疗和/或预防疾病的用途，以及其用于生产治疗和/或预防疾病，特别是治疗和/或预防心血管疾病和/或肾脏疾病的药物。